Does Wellbutrin Cause Palpitations?
Yes, Wellbutrin (bupropion) can cause palpitations, and this is a documented adverse effect that occurs at a clinically meaningful rate, particularly at higher doses (400 mg/day).
Evidence from FDA Drug Labeling
The FDA-approved drug label for Wellbutrin explicitly lists palpitation as a commonly observed adverse reaction 1. Specifically, palpitations occurred in at least 5% of patients treated with bupropion HCl sustained-release at 400 mg/day and at a rate at least twice that of placebo 1. This establishes palpitations as a recognized, dose-related adverse effect of the medication.
Clinical Context and Cardiovascular Monitoring
When prescribing bupropion, particularly in combination formulations like naltrexone/bupropion ER (Contrave), careful monitoring of heart rate and blood pressure is essential. Multiple clinical guidelines emphasize this:
- The 2016 AACE/ACE obesity guidelines specifically recommend that heart rate should be carefully monitored in patients receiving naltrexone ER/bupropion ER 2
- The 2025 AACE consensus statement notes that a slight elevation in blood pressure and heart rate have been observed with naltrexone/bupropion ER, requiring monitoring at the start of therapy and at regular intervals 3
Cardiovascular Risk Stratification
For patients with cardiac arrhythmia history or risk:
- Naltrexone ER/bupropion ER (which contains bupropion) is not contraindicated but should be used cautiously with careful monitoring of heart rate and rhythm 2
- Orlistat and lorcaserin are preferred alternatives in patients with a history or risk of cardiac arrhythmia 2
Dose-Related Considerations
The cardiovascular effects appear dose-dependent:
- At 300 mg/day: palpitations were not among the most common adverse effects
- At 400 mg/day: palpitations occurred at ≥5% incidence and at twice the placebo rate 1
- Research data shows tachycardia occurred in 5.5% of patients taking extra doses 4
Clinical Comparison to Other Antidepressants
Importantly, bupropion appears to have a wider cardiovascular safety margin compared to tricyclic antidepressants like nortriptyline 5. While nortriptyline caused significant heart rate increases (14.5-18 bpm) and cardiac conduction slowing, bupropion-treated patients had only small increases in diastolic blood pressure without the cardiac conduction changes 5.
Practical Management
If a patient on bupropion reports palpitations:
- Verify the current dose (higher doses carry greater risk)
- Check for concurrent medications that may interact (beta blockers, stimulants)
- Monitor vital signs including heart rate and blood pressure
- Consider dose reduction if clinically appropriate
- Evaluate for other cardiovascular risk factors or contraindications (uncontrolled hypertension, recent cardiac events)
Common pitfall: Failing to recognize that palpitations may be an early warning sign of more serious cardiovascular effects, particularly in overdose situations where tachycardia is associated with increased risk of adverse cardiovascular events 6.